Clin2
NCT04935853Possibly a fitRecruiting

Study of markers that predict bile duct cancer treatment response

Biliary Tract Cancer

Part of Cancer, Digestive system clinical trials.

This study looks at lab markers (including genetic tests) to predict how people with bile duct cancer respond to treatment. Your answers and samples may help doctors personalize care for bile duct cancer in the future.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
1,350 people
Ages
18 years and older
Study type
Observational

Who can take part

  • Be 18 years or older
  • Have bile duct cancer (intrahepatic or extrahepatic), or gallbladder/ bile duct adenocarcinoma; ampullomas are not included
  • Your diagnosis must be dated between 2003 and 2030
  • Be able to provide consent for genetic studies (unless an exception applies for a deceased patient)
  • Not be pregnant or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05184400Recruiting
Find new blood or tumor markers for bile duct and gallbladder cancer

This study looks for new ways to measure cancer-related “biomarkers” (signals in blood or tumor samples) in people with bile duct cancer or gallbladder cancer. The goal is to improve how these cancers are identified and tracked, which could help doctors make better treatment decisions.

Herlev, Copenhagen
NCT07151118Recruiting
Blood test for advanced biliary tract cancer

This study uses a simple blood test (ctDNA) to learn more about the genetic makeup of advanced biliary tract cancers. It may help researchers understand how these cancers respond to treatment, and it doesn't involve any extra drugs or procedures—just blood draws.

Seongnam-si, Gyeonggi-do
NCT07156058Recruiting
Personalized therapy after surgery for bile duct cancer

This trial uses a test called MiniPDX, which grows a tiny sample of your tumor in mice to see which drugs work best. After your surgery, you'll receive chemotherapy chosen specifically for your cancer to help prevent it from coming back.

Beijing
NCT06648057Recruiting
Predictors of response in biliary tract cancer

This trial is looking at how certain markers in your blood or tissue (biomarkers) might predict how well the combination of Lenvatinib and Pembrolizumab works against advanced biliary tract cancer. If you're already scheduled to receive these two drugs, researchers want to learn more from your samples to help future patients.

Seongnam-si, Gyeonggi-do
NCT04340986Recruiting
Group study for bile duct or liver cancer patients

This study follows people with bile duct cancer or certain liver cancers to better understand their disease. You might be included if you meet the diagnosis and basic participation requirements.

Paris
NCT05179486Recruiting
Study genes and blood markers in bile duct and gallbladder cancers

This study looks at genetic and molecular patterns in people with bile duct or gallbladder cancers, and compares them with people without cancer (or with chronic liver disease). It may help researchers understand why these cancers happen and how to spot risk earlier.

Houston, Texas

Hear when a new Biliary Tract Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.